We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 0.88% | 65.35 | 65.01 | 65.45 | 65.56 | 64.34 | 64.78 | 7,186,909 | 23:23:29 |
From May 2021 to May 2024
By Kimberly Chin
Gilead Sciences Inc. swung to a profit in the second quarter as revenue increased 21% driven by higher demand for therapies such as remdesivir, Biktarvy and its hepatitis C virus products as well as stronger demand for Trodelvy and Tecartus in the U.S.
The biopharmaceutical company's net profit was $1.52 billion, compared with a loss of $3.34 billion a year earlier. Earnings were $1.21 a share for the quarter, compared with a loss of $2.66 a shaer a year ago. Excluding special items, Gilead posted an adjusted profit of $1.87 a share. Analysts polled by FactSet were expecting adjusted earnings of $1.74 a share.
Total revenue rose to $6.22 billion from $5.14 billion in the year-earlier period. Analysts estimated $6.08 billion in revenue. Sales of its flagship HIV therapy Biktarvy increased by 24% from the prior year.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
July 29, 2021 16:29 ET (20:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
